INTRODUCTION
hypoglycemia (serum glucose 25 mg/dL). However, at that time, he refused further evaluation. He continued to experience similar symptoms almost daily for the next ten years, including dizziness, headache, slurred speech, and abnormal behavior (murmuring, drooling, and agitation) without consciousness. Symptoms usually occurred during sleep at night in addition to being aggravated by hunger and exercise, and were relieved by glucose intake. On admission, his body temperature and vital signs were normal. He appeared well and was not in acute distress, but reported slow speech and an impaired sense of direction.
All routine laboratory parameters were within normal ranges except for a low blood glucose level (53 mg/dL) and elevated levels of serum insulin (75.5 μU/mL), pro insulin (637.9 pmol/L), and c-peptide (8.17 ng/mL). We investigated for the possibility of accompanying multiple endocrine neoplasia type I. Basal pituitary hormone levels were within normal ranges (growth hormone 0.08 ng/mL, thyroid stimulating hormone 4.32 uU/mL, luteinizing hormone 6.12 mlU/mL, follicle stimulating hormone 5.78 mlU/mL, prolactin 21.45 n g/m L) e x c e p t f o r a n e l e v a t e d l e v e l o f adrenocorticotropic hormone (61.40 pg/mL). There were no features of multiple endocrine neoplasia type I in an overnight dexamethasone suppression test, or on a sellar magnetic resonance image or p a r a t h y r o i d s c a n. A p a n c r e a s c o m p u t e d tomography scan and transhepatic portal venous sampling were performed to localize the insulinoma. The computed tomography scan showed an enhanced 8-mm nodule in the superior a s p e c t o f t h e p a n c r e a t i c b o d y (F i g. 1A). Transhepatic portal venous sampling showed an elevated serum insulin level of 662.7 μU/mL in the body of pancreas (Fig. 1B) .
Surgical resection of the insulinoma at the body of the pancreas was performed. The mass was 2-cm in diameter, well-demarcated, and solid, with a pale yellowish color. Microscopic study demonstrated a solid, trabecular, and gyriform growth pattern. The tumor cells had small and relatively uniform nuclei with granular cytoplasm. Hyalinized stroma with calcification was evident (Fig. 2) .
Three days after the operation, the patient's serum insulin and c-peptide levels returned to normal (serum insulin 8.4 μU/mL, serum c-peptide 1.80 ng/mL). However, his slow speech and the impaired sense of direction did not return to normal. To examine the cognitive dysfunction, a neuropsychological battery of tests (K-MMSE, Attention, Language fluency, Controlled Oral Word Association Test, and Seoul Verbal Learning Test)
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At that time, cognitive impairment was normalized (total percentile score on the K-MMSE of 36.32). Spontaneous speech was fluent, and both verbal memory and frontal lobe dysfunction had improved relative to the immediate post-surgery time point (immediate recall total percentile score of 31.92, phonemic total percentile score of 18.94).
DISCUSSION
Neuroglycopenic manifestations are common in patients with insulinoma, but are frequently m i s d i a g n o s e d b e c a u s e o f t h e i r u n u s u a l manifestations. Failure to recognize the presence of a n i n s u l i n o m a m a y r e s u l t i n p e r m a n e n t neurological damage, or even death [8] . The brain regions most vulnerable to hypoglycemia are cornu ammonis area 1, subiculum, dentate gyrus of the hippocampus, and the outer layers of the cortex. All of these regions are important for learning and memory [9] . Patients who recover from severe hypoglycemia may be left with cognitive dysfunction, particularly short-term memory [10] .
T h e p a t h o p h y s i o l o g y o f h y p o g l y c e m i c encephalopathy is poorly understood. However, it is known that hypoglycemic neuronal injury is precipitated almost entirely by sustained glutamate receptor activation (excitotoxicity), which is mediated by Poly ADP-ribose polymerase-1 (P A R P-1) [11, 12] . T h e o n l y t r e a t m e n t f o r hypoglycemic brain damage is blood glucose repletion and, currently, there are no useful interventions to prevent the neuronal death that develops after correction of hypoglycemia. Pretreatment using glutamate receptor antagonists has been investigated in an attempt to reduce hypoglycemic neuronal death, but these agents are neurotoxic themselves and less effective when administered after hypoglycemia has occurred [13] . According to Suh et al. [14] , PARP-1 activation has a pivotal role in the development of hypoglycemic neuronal death and these authors provide proof of principle that PARP-1 inhibition can rescue neurons that would otherwise die after severe hypoglycemia. However, these treatments are not yet available, so the early diagnosis of insulinoma is crucial in patients with atypical neuroglycopenic presentation.
According to Daggett et al. [8] , the most common neuropsychiatric manifestations of insulinoma are confusion, coma, and convulsions; less common symptoms are blurred vision, paresthesiae, diplopia, paralysis including hemiplegia, monoplegia, and paraplegia. Therefore, blood glucose levels should always be checked in patients with neurologic deficits. When neurologic symptoms are recurrent and associated with hypoglycemia in non-diabetic patients, serum insulin levels must be checked to rule out insulinoma. Normally, when blood glucose levels decrease, insulin production is reduced. In β-cell adenomas, the production of insulin is elevated despite decreased blood glucose levels. In our study, the patient suffered from atypical neurologic symptoms for ten years. When he visited the Emergency Department ten years prior, insulinoma was suspected; however, he refused further evaluation and was discharged. Untreated insulinoma leads to cognitive dysfunction. According to Tam et al. [15] , hypoglycemia is associated with a higher risk of adverse motor and cognitive outcomes at 12 months of age in infants with neonatal encephalopathy. A previous study also highlights the impact of hypoglycemia on cognitive function in diabetic subjects who developed the condition in childhood [10] . However, insulinoma accompanying cognitive dysfunction is rare. There have been many studies focusing on neuroglycopenic symptoms of insulinoma; however, as far as we aware, this is the first case documenting cognitive dysfunction and frontal lobe dysfunction caused by insulinoma.
